About: Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
Creator	Jiang, Shibo Lu, Lu Xu, Wei Pu, Jing Wang, Qian
Source	PMC
abstract	Application of highly active antiretroviral drugs (ARDs) effectively reduces morbidity and mortality in HIV-infected individuals. However, the emergence of multiple drug-resistant strains has led to the increased failure of ARDs, thus calling for the development of anti-HIV drugs with targets or mechanisms of action different from those of the current ARDs. The first peptide-based HIV entry inhibitor, enfuvirtide, was approved by the U.S. FDA in 2003 for treatment of HIV/AIDS patients who have failed to respond to the current ARDs, which has stimulated the development of several series of protein- and peptide-based HIV entry inhibitors in preclinical and clinical studies. In this review, we highlighted the properties and mechanisms of action for those promising protein- and peptide-based HIV entry inhibitors targeting the HIV-1 gp120 or gp41 and discussed their advantages and disadvantages, compared with the current ARDs.
has issue date	2019-08-01(xsd:dateTime)
bibo:doi	10.3390/v11080705
bibo:pmid	31374953
has license	cc-by
sha1sum (hex)	62c1b83631e0a74cb6f73b5c46460769271c21b2
schema:url	https://doi.org/10.3390/v11080705
resource representing a document's title	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
has PubMed Central identifier	PMC6722851
has PubMed identifier	31374953
schema:publication	Viruses
resource representing a document's body	covid:62c1b83631e0a74cb6f73b5c46460769271c21b2#body_text
is schema:about of	named entity 'PEPTIDE' named entity 'ARDs' named entity 'active' named entity 'development' named entity 'patients' named entity 'reduces' named entity 'HIV' named entity 'HIV ENTRY INHIBITORS' named entity 'PROTEIN' named entity 'ENFUVIRTIDE' named entity 'HIV' named entity 'INCREASED' named entity 'GP41' named entity 'BASED' named entity 'PROTEIN' named entity 'FAILURE' named entity 'RESISTANT' named entity 'FDA' named entity 'DRUGS' named entity 'APPLICATION' named entity 'VIRUSES' named entity 'GP41' named entity 'CURRENT' named entity 'DEVELOPMENT' named entity 'BASED' named entity 'GP120' named entity 'TO RESPOND' named entity 'HIGHLY' named entity 'GP120' named entity 'PROPERTIES' named entity 'MORBIDITY AND MORTALITY' named entity 'ACTIVE' named entity 'THEIR' named entity 'DIFFERENT' named entity 'LED' named entity 'APPROVED BY' named entity 'U.S.' named entity 'SERIES' named entity 'ACTION' named entity 'TREATMENT' named entity 'COMPARED' named entity 'HAVE' named entity 'MECHANISMS' named entity 'DEVELOPMENT' named entity 'PATIENTS' named entity 'STRAINS' named entity 'EMERGENCE' named entity 'DRUG' named entity 'REVIEW' named entity 'STIMULATED' named entity 'HIV-1' named entity 'HIV ENTRY INHIBITOR' named entity 'PRECLINICAL AND CLINICAL STUDIES' named entity 'INDIVIDUALS' named entity 'RESPOND TO' named entity 'FAILED' named entity 'INFECTED' named entity 'MULTIPLE' named entity 'ARDS' named entity 'TARGETS' named entity 'ANTIRETROVIRAL' named entity 'TARGETING' named entity 'TARGETING' named entity 'PEPTIDE' named entity 'CALLING' named entity 'ANTI-HIV DRUGS' covid:arg/62c1b83631e0a74cb6f73b5c46460769271c21b2 named entity 'action' named entity 'targeting' named entity 'gp41' named entity 'HIV-1' named entity 'However' named entity 'HIV' named entity 'helix' named entity 'assay' named entity 'recombinant protein' named entity 'Env'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software